Novartis faces whistleblower claims of bribery in Turkey

Novartis ($NVS) faces bribery allegations in yet another country. A whistleblower has accused the Swiss drugmaker of paying bribes in Turkey to increase prescriptions of its drugs, Reuters reports. More from FiercePharma

Suggested Articles

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.

The FDA wants to know what, exactly, is in a drug name—and whether it influences how the product is perceived. So it's launching a study to find out.

Horizon Therapeutics has notched an FDA approval for its rare eye disease med Tepezza (teprotumumab), a possible blockbuster drug in the making.